Related Experiment Video
Updated: Mar 28, 2026
Investigating the Effects of Probiotics on Pneumococcal Colonization Using an In Vitro Adherence Assay
Published on: April 28, 2014
Verbascoside Alleviates Pneumococcal Pneumonia by Reducing Pneumolysin Oligomers
Xiaoran Zhao1, Hongen Li1, Jianfeng Wang1
1Key Laboratory of Zoonosis, Ministry of Education, College of Veterinary Medicine, Jilin University, Changchun, China (X.Z., H.L., J.F., Y.G., B.L., X.D.); and Key Laboratory of Zoonosis, Ministry of Education, Department of Food Quality and Safety, Jilin University, Changchun, China (X.N.).
Verbascoside (VBS) inhibits pneumolysin (PLY), a key Streptococcus pneumoniae virulence factor, by blocking its pore formation. This novel therapeutic approach protects against pneumococcal pneumonia and reduces mortality in animal models.
Area of Science:
- Microbiology
- Pharmacology
- Immunology
Background:
- Pneumolysin (PLY) is a critical virulence factor of Streptococcus pneumoniae, contributing to host defense penetration and inflammation.
- Targeting PLY is a promising strategy for treating pneumococcal infections due to its essential role in pathogenesis.
- Verbascoside (VBS) is a non-bacteriostatic agent that inhibits PLY-mediated cytotoxicity.
Purpose of the Study:
- To investigate the mechanism by which Verbascoside (VBS) inhibits pneumolysin (PLY).
- To evaluate the therapeutic potential of VBS against pneumolysin-induced lung injury and pneumococcal pneumonia.
Main Methods:
- Molecular dynamics simulations and mutational analysis to determine VBS binding site on PLY.
- In vitro assays using human alveolar epithelial (A549) cells to assess VBS's protective effects against PLY-mediated injury.
- In vivo studies using a murine model of pneumococcal pneumonia to evaluate VBS efficacy in reducing lung damage and mortality.
Main Results:
- VBS binds to the cleft between domains 3 and 4 of PLY, inhibiting its oligomerization and hemolytic activity.
- VBS significantly alleviates PLY-induced injury in A549 cells.
- VBS treatment protects mice against lung damage and reduces mortality in a pneumococcal pneumonia model.
Conclusions:
- Verbascoside effectively neutralizes pneumolysin's cytotoxic effects by disrupting its oligomerization.
- VBS demonstrates significant therapeutic potential as a novel treatment for Streptococcus pneumoniae infections.
- VBS represents a promising candidate for developing new therapies against pneumococcal diseases.
More Related Videos
11:32Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
12:21A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness
Published on: September 28, 2022
Related Concept Videos
01:14Atypical Pneumonia
01:29Pneumonia II: Pathophysiology
01:28Gene Regulation in Microbial Communities: Quorum Sensing
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
01:30Pneumonia III: Complications and Assessment